SynAct Pharma

SynAct Pharma is a clinical-stage biotechnology company that focuses on treatments with the ability to resolve rather than inhibit ongoing inflammatory processes in acute and chronic diseases. Its lead compound, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key effector cells in the immune system. The company was formed as SynAct Pharma ApS in 2012, and its parent company SynAct Pharma AB was formed in April 2016. The company's shares are listed on the mid-Cap segment at Nasdaq Stockholm's main market.

SynAct Pharma ApS was formed in 2012. SynAct Pharma AB, the Group's parent company, was formed in April 2016. In 2022, the company's shares were listed on the mid-Cap segment at Nasdaq Stockholm's main market. In 2023, the company acquired TXP Pharma AG and integrated the portfolio of peptide melanocortin agonists in the pipeline. The lead compound is TXP-11. Resomelagon was assigned as International Nonproprietary Name (INN) for AP1189 by WHO. In 2024, the Phase 2b ADVANCE study in Rheumatoid Arthritis was initiated. In 2025, the RESOVIR-2 study in Dengue was initiated in Q2.

• 2026.10.27

  Reported2026.10.27

  SynAct Pharma and Hipolabor enter dengue-treatment partnership in Brazil[5]SynAct Pharma与Hipolabor达成巴西登革热治疗合作finanznachrichten.de

  SynAct Pharma announced that it entered into a strategic co-development and commercialization agreement with Hipolabor for resomelagon as a dengue treatment in Brazil. The agreement provides for equal sharing of development costs and profits.

Read more

1. 1SynAct Pharma – A Clinical-Stage Biotechnology Companysynactpharma.com
2. 2History – SynAct Pharmasynactpharma.com
3. 3About – SynAct Pharmasynactpharma.com
4. 4Synact Pharmawikidata.org
5. 5SynAct Pharma与Hipolabor达成巴西登革热治疗合作finanznachrichten.de